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Reply to Eisen and McBryde
TO THE EDITOR—Eisen and McBryde [1]
support the conclusion of our experimen-
tal study on antiplatelet prophylaxis of
experimental infective endocarditis (IE)
and the need to further investigate new
drugs of the anti-GPIIb/IIIa receptor
class (eg, abciximab) that could be given
orally. Their argument is based on both
the greater ability of abciximab than
more classic aspirin-plus-ticlopidine regi-
men to prevent experimental IE caused
by both streptococci and staphylococci,
and on their meta-analysis showing that
classical antiplatelet therapy given in es-
tablished IE provided a beneﬁt in terms
of embolus prevention, which was coun-
terbalanced by a risk of increased overall
mortality. Thus, there is a proof of con-
cept for a beneﬁt of antiplatelet regimens
in both IE prevention and therapy, but
improved drugs and drug formulations
must be sought.
We support the argument of Eisen and
McBryde that further development on
anti-GPIIb/IIIa drugs could represent an
improvement for IE prevention in select-
ed at-risk patients. However, we would
not entirely discard a potential beneﬁt
from more classical antiplatelet regimens,
as they did show a signiﬁcant protective
effect against experimental IE caused by
both Streptococcus gordonii and Staphylo-
coccus aureus experimental IE, although
abciximab was more effective.
Eisen and McBryde’s arguments are
based on the relatively limited (although
not null) efﬁcacy of classical antiplatelet
regimens (mainly aspirin) to prevent em-
bolism in established IE. They also em-
phasize that antiaggregant therapy should
be given before the onset of IE rather than
after IE establishment. Indeed, early anti-
aggregant therapy may decrease the size
of nascent vegetations and impede their
further enlargement, whereas late antiag-
gregant therapy might favor vegetation
dislodgment and bleeding in embolized
areas [2].
The fact that antiaggregant given be-
fore IE is not a risk factor for increased
embolism in case of later IE development
is critical, as it does not prohibit antiag-
gregants as a prophylactic measure in
at-risk patients, at least with classical
drugs. The question, however, is whether
or not chronic use of aspirin or other an-
tiplatelet drugs might protect patients
from IE development.We sought to deter-
mine whether existing human data could
providesomecluestoanswer thisquestion.
Unfortunately, neither the Framingham
Heart Study cohort nor the International
Collaboration on Endocarditis database
could provide deﬁnitive information on
thisspeciﬁc issue.Therefore,wearecurrently
planning a prospective observational study
in patients with bioprosthetic heart valves
receiving or not receiving thrombosis pro-
phylaxis with antiplatelet drugs.
We also would like to emphasize the
protective effect of the new-generation
thrombin inhibitor dabigatran against S.
aureus experimental IE. Control aceno-
coumarol did not protect against either
streptococcal or staphylococcal experi-
mental IE, whereas dabigatran speciﬁ-
cally protected against S. aureus IE. This
is likely associated with the observation
that dabigatran inhibits not only thrombin,
but also the S. aureus coagulase, which can
bypass thrombin and polymerize ﬁbrino-
gen into ﬁbrin, even in acenocoumarol-
or citrate-anticoagulated blood. The dual
anticoagulant and anti–S. aureus activity
of dabigatran would be ideal in patients
with prosthetic valves, in whom S. aureus
IE is lethal in close to 50% of cases [3, 4].
Unfortunately, dabigatran did not do well
in such patients [5, 6].While further phar-
macologic development is required before
dabigatran can be used in prosthetic valves,
it opens yet another strategy for S. aureus
IE prevention.
We agree with Eisen and McBryde that
more developments are needed regarding
the prevention and treatment of IE. Re-
garding prevention, we have abandoned
antibiotic prophylaxis overkill, which
was based on intuitive rather than evi-
dence-based medicine [7, 8]. Yet, IE is a
persistent Damocles sword in at-risk pa-
tients, as it can happen at any time during
their life. Simple alternatives are needed
for these patients, and chronic use of
antiplatelet drugs could be one of them.
Regarding therapy, 2–6 week courses of
parenteral antibiotics are still the standard.











We think that numerous improvements
are possible, including adjunctive therapy
that could interfere with vegetation devel-
opment, promote its resolution, and help
bacterial clearance. Indeed, while further
improvements in antiaggregant drugs
seem a promising approach, other innova-
tive options must also be considered, such
as decreasing embolic events in patients
suffering IE and chronically treated with
statins [9], where pleomorphic activity
might reveal as yet unexpected beneﬁts.
New imaginative strategies are welcome
to solve the IE problem.
Note
Potential conﬂicts of interest. All authors:
No reported conﬂicts.
All authors have submitted the ICMJE Form
for Disclosure of Potential Conﬂicts of Interest.
Conﬂicts that the editors consider relevant to the
content of the manuscript have been disclosed.
Tiago Rafael Veloso,1 Yok-Ai Que,2
Philippe Moreillon,1 and José Manuel Entenza1
1Department of Fundamental Microbiology, University
of Lausanne, and 2Department of Intensive Care
Medicine, University Hospital Medical Center, (CHUV)
and University of Lausanne, Switzerland
References
1. Eisen DP, McBryde ES. An association between
aspirin use in human cases of infective endo-
carditis and reduced systemic embolism is
shown in meta-analysis of observational stud-
ies. J Infect Dis 2015; 212:673–4.
2. Chan K-L, Dumesnil JG, Cujec B, et al. A ran-
domized trial of aspirin on the risk of embolic
events in patients with infective endocarditis. J
Am Coll Cardiol 2003; 42:775–80.
3. Chirouze C, Miro JM, Cabell CH, et al. Prog-
nostic factors in 61 cases of Staphylococcus au-
reus prosthetic valve infective endocarditis
from the International Collaboration on En-
docarditis merged database. Clin Infect Dis
2004; 38:1323–7.
4. Hill EE, Herijgers P, Claus P, Vanderschueren
S, Herregods M, Peetermans WE. Infective
endocarditis: changing epidemiology and
predictors of 6-month mortality: a prospec-
tive cohort study. Eur Heart J 2007; 28:
196–203.
5. Van de Werf F, Brueckmann M, Connolly SJ,
et al. A comparison of dabigatran etexilate
with warfarin in patients with mechanical
heart valves: THE Randomized, phase II
study to evaluate the safety and pharmacoki-
netics of oral dabigatran etexilate in patients
after heart valve replacement (RE-ALIGN).
Am Heart J 2012; 163:931–7.
6. Eikelboom JW, Connolly SJ, Brueckmann M,
et al. Dabigatran versus warfarin in patients
with mechanical heart valves. N Engl J Med
2013; 369:1206–14.
7. Wilson W, Taubert KA, Gewitz M, et al. Pre-
vention of infective endocarditis: guidelines
from the American Heart Association: a
guideline from the American Heart Associa-
tion Rheumatic Fever, Endocarditis, and
Kawasaki Disease Committee, Council on
Cardiovascular Disease in the Young, and
the Council on Clinical Cardiology, Council
on Cardiovascular Surgery and Anesthesia,
and the Quality of Care and Outcomes
Research Interdisciplinary Working Group.
Circulation 2007; 116:1736–54.
8. Thuny F, Grisoli D, Cautela J, Riberi A, Raoult
D, Habib G. Infective endocarditis: preven-
tion, diagnosis, and management. Can J
Cardiol 2014; 30:1046–57.
9. AnavekarNS, Schultz JC,De SaDDC, et al.Mod-
iﬁers of symptomatic embolic risk in infective
endocarditis. Mayo Clin Proc 2011; 86:1068–74.
Received 23 February 2015; accepted 24 February 2015;
electronically published 9 March 2015.
Correspondence: José Manuel Entenza, Department of
Fundamental Microbiology, University of Lausanne, CH-1015
Lausanne, Switzerland (jose.entenza@unil.ch).
The Journal of Infectious Diseases® 2015;212:674–5
© The Author 2015. Published by Oxford University Press
on behalf of the Infectious Diseases Society of America. All
rights reserved. For Permissions, please e-mail: journals.
permissions@oup.com.
DOI: 10.1093/infdis/jiv133




niversity Library on O
ctober 19, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
